

If a conflict arises between a Clinical Payment and Coding Policy and any plan document under which a member is entitled to Covered Services, the plan document will govern. If a conflict arises between a CPCP and any provider contract pursuant to which a provider participates in and/or provides Covered Services to eligible member(s) and/or plans, the provider contract will govern. "Plan documents" include, but are not limited to, Certificates of Health Care Benefits, benefit booklets, Summary Plan Descriptions, and other coverage documents. Blue Cross and Blue Shield of Illinois may use reasonable discretion interpreting and applying this policy to services being delivered in a particular case. BCBSIL has full and final discretionary authority for their interpretation and application to the extent provided under any applicable plan documents.

Providers are responsible for submission of accurate documentation of services performed. Providers are expected to submit claims for services rendered using valid code combinations from Health Insurance Portability and Accountability Act approved code sets. Claims should be coded appropriately according to industry standard coding guidelines including, but not limited to: Uniform Billing Editor, American Medical Association, Current Procedural Terminology, CPT® Assistant, Healthcare Common Procedure Coding System, ICD-10 CM and PCS, National Drug Codes, Diagnosis Related Group guidelines, Centers for Medicare and Medicaid Services National Correct Coding Initiative Policy Manual, CCI table edits and other CMS guidelines.

Claims are subject to the code edit protocols for services/procedures billed. Claim submissions are subject to claim review including but not limited to, any terms of benefit coverage, provider contract language, medical policies, clinical payment and coding policies as well as coding software logic. Upon request, the provider is urged to submit any additional documentation.

Preventive Services Policy

Policy Number: CPCP006

Version: 1.0

Enterprise Clinical Payment and Coding Policy Committee Approval Date: Dec. 15, 2025

Effective Date: Jan. 1, 2026

Definitions

The following acronyms have been utilized throughout this reimbursement policy.

| | |
|----------------|--|
| ACIP: | Advisory Committee on Immunization Practices |
| CDC: | Centers for Disease Control and Prevention |
| FDA: | United States Food and Drug Administration |
| HRSA: | Health Resources and Services Administration |
| PPACA: | Patient Protection and Affordable Care Act of 2010 |
| USPSTF: | United States Preventive Services Task Force |

Description

Section 2713 of the Patient Protection and Affordable Care Act mandates that private health plans provide coverage of preventive services issued by the following agencies: The United States Preventive Services Task Force , the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention , and the Health Resources and Service Administration with respect to women's guidelines and guidelines for infants, children, and adolescents. These services are available at no cost-share when obtained by a member covered under a non-grandfathered plan. This applies to members belonging to individual, small group, large group, and self-insured plans. There is no copay, deductible or coinsurance, even if the individual or family deductible or out-of-pocket maximum has not been met as long as the member utilizes a provider in the plan's network.

Preventive care or preventive medicine refers to measures or services taken to promote health and early detection/prevention of disease(s) and injuries rather than treating them and/or curing them. Preventive care may include, but are not limited to, examinations and screening tests tailored to an individual's age, health, and family history.

PPACA does not mandate that preventive services be covered at no member cost-share when obtained out-of-network. Members that obtain preventive services out of their network will be subject to copay, deductible, and coinsurance.

Grandfathered plans are plans that have been in existence prior to March 23, 2010 and are exempt from the requirement of providing preventive services at no member cost share. Grandfathered plans have the opportunity to elect providing coverage of preventive services at no member cost share but are not required to do so.

The USPSTF applies a [letter grade](#) for each of the recommendations that are released.

Following the [recommendation](#) of the USPTF coverage of Grade “A” and “B” recommendations is provided at no member cost share for members with a non-grandfathered health plan.

| Grade | Definition |
|----------|--|
| A | The USPSTF recommends the service. There is high certainty that the net benefit is substantial. |
| B | The USPSTF recommends the service. There is high certainty that the net benefit is moderate or there is moderate certainty that the net benefit is moderate to substantial. |
| C | The USPSTF recommends selectively offering or providing this service to individual patients based on professional judgment and patient preferences. There is at least moderate certainty that the net benefit is small. |
| D | The USPSTF recommends against the service. There is moderate or high certainty that the service has no net benefit or that the harms outweigh the benefits. |
| I | The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of the service. Evidence is lacking, of poor quality, or conflicting, and the balance of benefits and harms cannot be determined. |

The ACIP publishes recommendations on the safe utilization of vaccines. ACIP’s [recommendations](#) include immunization schedules for children and adolescents as well as adults. Immunizations should be administered in accordance with the ACIP Recommended Child and Adult Immunization Schedules or in accordance with state law or regulations.

HRSA releases [Women’s Preventive Services guidelines](#) that are aimed at improving women’s health by recommending certain preventive services that should be obtained in the clinical setting.

HRSA endorses [preventive guidelines](#) established by the American Academy of Pediatrics for the health and well-being of infants, children, and adolescents. These recommendations are referred to as Bright Futures.

Reimbursement Information

Certain preventive care services may be considered eligible for coverage under the member's benefit plan as required by PPACA and/or an applicable state mandate. In general, these services include, but are not limited to, screenings, immunizations, and other types of care as recommended by the United States Federal Government.

These services are not subject to application of cost-sharing such as co-payments, co-insurance or deductibles when they are considered eligible for coverage and are provided by a network provider. In order for preventive claims to process at the preventive level with no member cost share, the claim must include a preventive diagnosis code, a preventive procedure code, meet medical policy review criteria, and fall within the guidelines issued by the USPSTF, ACIP, HRSA, or Bright Futures.

Health care providers (facilities, physicians and other health care professionals) are expected to exercise independent medical judgement in providing care to patients. This Preventive Services Reimbursement policy is not intended to impact care decisions or medical practice.

The following grid provides a list of the recommendations released by the USPSTF, ACIP, HRSA, or Bright Futures along with the corresponding procedure codes and diagnosis codes deemed to be preventive.

| USPSTF Recommendations: | | |
|--|---|--|
| Service: | Procedure Code(s): | Additional Reimbursement Criteria: |
| Abdominal Aortic Aneurysm Screening <u>USPSTF "B" Recommendation</u> <u>December 2019</u> The USPSTF recommends 1-time screening for abdominal aortic aneurysm with ultrasonography in men aged 65 to 75 years who have ever smoked. | 76706 | Procedure code 76706 is reimbursable as preventive when submitted with one of the following: Z13.6, Z87.891, Z72.0, Z00.00, Z00.01, F17.210, F17.200 |
| Unhealthy Alcohol Use in Adolescents and Adults: Screening and Behavioral Counseling Interventions | 99385, 99386, 99387, 99395, 99396, 99397, 99408, 99409, | Payable with a diagnosis code in Diagnosis List 1. |

| | | |
|--|---|---|
| <p><u>USPSTF “B” Recommendation November 2018</u></p> <p>The USPSTF recommends screening for unhealthy alcohol use in primary care settings for adults 18 years or older, including pregnant women, and providing persons engaged in risky or hazardous drinking with brief behavioral counseling interventions to reduce unhealthy alcohol use.</p> | <p>G0396, G0397, G0442, G0443</p> | |
| <p>Anxiety Screening Disorders in Adults</p> <p><u>USPSTF Released FINAL “B” Recommendation for Screening for Anxiety Disorders in Adults 06/30/2023</u></p> <p>The USPSTF recommends screening for anxiety disorders in adults, including pregnant and postpartum persons.</p> | <p>96127, 99384, 99385, 99386, 99387, 99394, 99395, 99396, 99397, G0444</p> | <p>Procedure code 96127 is only reimbursable at the preventive level when billed with a diagnosis of Z00.129, Z13.31, Z13.32, Z13.39, Z13.41, or Z13.42</p> |
| <p>Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: Preventive Medication</p> <p><u>USPSTF “B” Recommendation September 2021</u></p> <p>The USPSTF recommends the use of low-dose aspirin (81 mg/day) as preventive medication after 12 weeks of gestation in persons who are at high risk for preeclampsia.</p> | | <p>For details about pharmacy benefit coverage, contact the number on the patient’s BCBSIL member card. A patient’s pharmacy benefit may be managed by a company other than BCBSIL.</p> <p>Coverage includes generic aspirin 81 mg tablets with a prescription.</p> |

| | | |
|--|---|--|
| <p>Asymptomatic Bacteriuria in Adults Screening</p> <p><u>USPSTF “B” Recommendation September 2019</u></p> <p>The USPSTF recommends screening for asymptomatic bacteriuria using urine culture in pregnant persons.</p> | <p>81007, 87086, 87088</p> | <p>Payable with a Pregnancy Diagnosis</p> |
| <p>BRCA-Related Cancer Risk Assessment, Genetic Testing</p> <p><u>USPSTF “B” Recommendation August 2019</u></p> <p>USPSTF recommends that primary care clinicians assess women with a personal or family history of breast, ovarian, tubal, or peritoneal cancer or who have an ancestry associated with breast cancer susceptibility 1 and 2 (BRCA1/2) gene mutations with an appropriate brief familial risk assessment tool. Women with a positive result on the risk assessment tool should receive genetic counseling and, if indicated after counseling, genetic testing.</p> | <p>81212, 81215, 81216, 81217, 81162, 81163, 81164, 81165, 81166, 81167, 99385, 99386, 99387, 99395, 99396, 99397, 99401, 99402, 99403, 99404, G0463, S0265, 81307, 81308 , 96041</p> | <p>These services are subject to Medical Policy and prior authorization may be required. Procedure codes 81212, 81215-81217, 81162-81167, 81307 and 81308 are reimbursable as preventive when submitted with one of the following primary diagnosis codes: Z80.3, Z80.41, Z85.3, Z85.43</p> <p>Procedure code 96041 is reimbursable as preventive when submitted with one of the following primary diagnosis codes: Z80.3 or Z80.41</p> <p>All other procedure codes for BRCA are payable with a diagnosis in Diagnosis List 1</p> |

| | | |
|--|---|---|
| <p>Breast Cancer Medications for Risk Reduction</p> <p><u>USPSTF “B” Recommendations September 2019</u></p> <p>The USPSTF recommends that clinicians offer to prescribe risk-reducing medications, such as tamoxifen, raloxifene, or aromatase inhibitors, to women who are at increased risk for breast cancer and at low risk for adverse medication effects.</p> | | <p>For details about pharmacy benefit coverage, contact the number on the patient’s BCBSIL member card. A patient’s pharmacy benefit may be managed by a company other than BCBSIL.</p> <p>Coverage includes generic anastrozole 1 mg, raloxifene hcl 60 mg, and tamoxifen citrate 10 and 20 mg tablets when used for prevention in members ages 35 and over with a prescription.</p> |
| <p>Breast Cancer Screening</p> <p><u>USPSTF “B” Recommendation January 2026</u></p> <p>The Women’s Preventive Services Initiative recommends that average-risk women initiate mammography screening no earlier than age 40 and no later than age 50. Screening mammography should occur at least biennially and as frequently as annually. Women may require additional imaging to complete the screening process or to address findings on the initial screening mammography. If additional imaging (e.g., magnetic resonance imaging (MRI), ultrasound, mammography) and pathology evaluation are indicated, these services also are recommended to</p> | <p>77061, 77062, 77063, 77067, 76376, 76377, 76641, 76642, 77046, 77048, 77049, 77065, 77066, C8903, C8905, C8906, C8908, C8937, G0279, 0633T, 0634T, 0635T, 0637T, 0638T, 19030, 77053, 77054</p> <p>88108, 88112, 88172, 88173, 88184, 88185, 88262, 88271, 88274, 88291, 88300, 88304, 88305, 88307, 88309, 88312, 88313, 88325,</p> | <p>Payable if billed with diagnosis: Z00.00, Z00.01, Z00.8, Z01.411, Z12.31, and Z12.39</p> |

| | | |
|---|--|--|
| complete the screening process for malignancies. Screening should continue through at least age 74 and age alone should not be the basis to discontinue screening. These screening recommendations are for women at average risk of breast cancer. Women at increased risk should also undergo periodic mammography screening, however, recommendations for additional services are beyond the scope of this recommendation | 88331, 88332, 88341, 88342, 88344, 88360, 83361, 88364, 88365, 88367, 88374, & 88377 | |
| Refer also to USPSTF's 'Breast Cancer Screening' recommendation. | 19081, 19082, 19083, 19084, 19085, 19086, 19100, 19101, 19281, 19282, 19283, 19284, 19285, 19286, 19287, 19288, 10004, 10005, 10006, 10007, 10008, 10009, 10010, 10011 10012, 10021 | |
| <i>Refer</i> also to HRSA's 'Breast Cancer Screening for Women at Average Risk' recommendation. | C7501, & C7502 | |
| | A9500, A9502, A9503, A9520, A9537, A9541, A9552, A9561, A9573, A9575, A9576, A9577, A9577, A9578, A9579, A9581, A49585, A9595, Q9950, Q9953, Q9954, Q9957, Q9958, Q9962, Q9963, Q9966, Q9967, Q9968, Q9969, Q9067, Q9953 & Q9954 | |
| | 96374, 96375, 01922, 99152, 99153, 99156, 99157, 76942, | |

| | | |
|---|--|--|
| | <p>77002, 77012, 88177, 0836T, 80503, 80504, 80505, 80506</p> <p>Patient Navigation Services: G0023, G0024, G0140, G0146</p> | |
| <p>Breastfeeding Primary Care Interventions</p> <p><u>USPSTF “B” Recommendation October 2016</u></p> <p>The USPSTF recommends providing interventions during pregnancy and after birth to support breastfeeding.</p> <p><i>Refer also to HRSA’s ‘Breastfeeding Services and Supplies’ recommendation</i></p> | <p>99401, 99402, 99403, 99404, 99411, 99412, 99347, 99348, 99349, 99350, 98960, 98961, 98962. G0513, G0514</p> <p>A4281, A4282, A4283, A4284, A4285, A4286, E0602, E0603, E0604, S9443, A4287, A4288</p> | <p>Electric breast pumps limited to one per benefit period. Hospital Grade breast pumps are limited to rental only.</p> <p>Additional reimbursement information available within the “Breastfeeding Equipment and Supplies”</p> <p>G0513 & G0514 are payable with a diagnosis code in Diagnosis List 1</p> <p>Non-physician provider types such as Certified Lactation Counselors and International Board-Certified Lactation Consultants will only be eligible for reimbursement for the following codes: S9443, 98960, 98961, 98962.</p> |

| | | |
|---|---|--|
| <p>Cervical Cancer Screening</p> <p><u>USPSTF “A” Recommendation</u> <u>August 2018</u></p> <p>The USPSTF recommends screening for cervical cancer every 3 years with cervical cytology alone in women aged 21 to 29 years. For women aged 30 to 65 years, the USPSTF recommends screening every 3 years with cervical cytology alone, every 5 years with high-risk human papillomavirus (hrHPV) testing alone, or every 5 years with hrHPV testing in combination with cytology (cotesting).</p> <p><i>Refer also to HRSA’s ‘Cervical Cancer Screening’ recommendation.</i></p> | <p>99385, 99386, 99387, 99395, 99396, 99397</p> <p>G0101, 88141, 88142, 88143, 88147, 88148, 88150, 88152, 88153, 88155, 88164, 88165, 88166, 88167, 88174, 88175, G0123, G0124, G0141, G0143, G0144, G0145, G0147, G0148, P3000, P3001, Q0091, 87623, 87624, 87625, S0610, S0612, 0096U, 87626</p> | <p>Payable with a diagnosis code in Diagnosis List 1</p> |
| <p>Chlamydia Screening</p> <p><u>USPSTF “B” Recommendations</u> <u>September 2021</u></p> <p>The USPSTF recommends screening for chlamydia in sexually active women age 24 years and younger and in women 25 years or older who are at increased risk for infection.</p> | <p>86631, 86632, 87110, 87270, 87320, 87490, 87491, 87492, 87801, 87810, 87494</p> | <p>Payable with a diagnosis code in Diagnosis List 1</p> |

| | | |
|--|---|--|
| <p>Colorectal Cancer Screening</p> <p><u>USPSTF “A” Recommendation May 2021</u></p> <p>The USPSTF recommends screening for colorectal cancer in all adults aged 50 to 75 years.</p> <p><u>USPSTF “B” Recommendation May 2021</u></p> <p>The USPSTF recommends screening for colorectal cancer in adults aged 45 to 49 years.</p> <p>The risks and benefits of different screening methods vary.</p> | <p>82270, 82274, G0328, 44388, 44389, 44392, 44394, 44401, 44404, 45378, 45380, 45381, 45384, 45385, 45388, G0105, G0121, 45330, 45331, 45333, 45335, 45338, 45346, 74263, 88304, 88305, G0104, 99202, 99203, 99204, 99205, 99211, 99212, 99213, 99214, 99215, 99417, S0285, 00812, 00813, 81528, 0464U</p> | <p>Certain colorectal cancer screening services may be subject to medical policy criteria and may require prior authorization.</p> <p>Modifier 33 or PT may be applied</p> <p>Payable with a diagnosis in Diagnosis List 1.</p> <p>In the instance that a polyp is removed during a preventive colonoscopy, the colonoscopy as well as the removal of the polyp and the labs and services related to the colonoscopy are reimbursable at the preventive level.</p> <p>Sedation procedure codes 99152, 99153, 99156, 99157, and G0500 will process at the preventive level when billed with a diagnosis of Z12.11 or Z12.12.</p> <p>Procedure code 74263 is reimbursable at the preventive level when billed with one of the following three diagnosis codes: Z00.00, Z12.11, Z12.12.</p> |
|--|---|--|

| | | |
|--|---------------------|--|
| | | <p>Procedure code 81528 is reimbursable at the preventive level when billed with Z12.11 or Z12.12 for out of network claims.</p> <p>For details about pharmacy benefit coverage, contact the number on the patient's BCBSIL member card. A patient's pharmacy benefit may be managed by a company other than BCBSIL.</p> <p>Coverage includes generic peg 3350-kcl-na bicarb-nacl-na sulfate, peg 3350-kcl-nacl-na sulfate-na ascorbate-c, or peg 3350-kcl-sod bicarb-nacl solutions for members ages 45 and over with a prescription.</p> <p>Diagnosis codes R19.5, K63.5, Z86.0100, Z86.0101, Z86.0102, Z86.0109 will pay at the preventive level.</p> |
| <p>Congenital Hypothyroidism Screening</p> <p><u>USPSTF "A" Recommendation March 2008</u></p> <p>The USPSTF recommends screening for congenital hypothyroidism in newborns.</p> | 84443, 99381, S3620 | |

| | | |
|--|---|---|
| <p>Dental Caries in Children from Birth Through Age 5 Years Screening</p> <p><u>USPSTF “B” Recommendation December 2021</u></p> <p>The USPSTF recommends that primary care clinicians prescribe oral fluoride supplementation starting at age 6 months for children whose water supply is deficient in fluoride.</p> <p><u>USPSTF “B” Recommendation December 2021</u></p> <p>The USPSTF recommends that primary care clinicians apply fluoride varnish to the primary teeth of all infants and children starting at the age of primary tooth eruption.</p> | <p>99188</p> | <p>For details about pharmacy benefit coverage, contact the number on the patient’s BCBSIL member card. A patient’s pharmacy benefit may be managed by a company other than BCBSIL.</p> <p>Prescription required for both OTC and prescription medications.</p> |
| <p>Depression Screening Adults</p> <p><u>USPSTF “B” Recommendation January 2016</u></p> <p>The USPSTF recommends screening for depression in the general adult population, including pregnant and postpartum women. Screening should be implemented with adequate systems in place to ensure accurate diagnosis, effective treatment, and appropriate follow-up.</p> <p><u>USPSTF Released FINAL “B” Recommendation for Screening for Depression and Suicide Risk in Adults</u></p> <p>Suicide Risk is an “I”</p> | <p>99385, 99386, 99387, 99395, 99396, 99397, 96160, 96161, G0444, 96127</p> | <p>Payable with a diagnosis code in Diagnosis List 1</p> <p>Procedure code 96127 is only reimbursable at the preventive level when billed with a diagnosis of Z00.129, Z13.31, Z13.32, Z13.39, Z13.41, or Z13.42</p> |

| | | |
|--|---|--|
| recommendation which does not apply to the CPCP. | | |
| <p>Depression in Children and Adolescents Screening</p> <p><u>USPSTF “B” Recommendation February 2016</u></p> <p>The USPSTF recommends screening for major depressive disorder in adolescents aged 12 to 18 years. Screening should be implemented with adequate systems in place to ensure accurate diagnosis, effective treatment, and appropriate follow-up.</p> <p><i>Refer also to Bright Futures ‘Depression Screening’ recommendation.</i></p> | 99384, 99385, 99394, 99395, 96127, G0444 | <p>Payable with a diagnosis in Diagnosis List 1</p> <p>Procedure code 96127 is only reimbursable at the preventive level when billed with a diagnosis of Z00.129, Z13.31, Z13.32, Z13.39, Z13.41, or Z13.42</p> |
| <p>Falls Prevention in Community Dwelling Older Adults: Interventions</p> <p><u>USPSTF “B” Recommendation April 2018</u></p> <p>The USPSTF recommends exercise interventions to prevent falls in community-dwelling adults aged 65 years or older who are at increased risk for falls.</p> | 97110, 97112, 97116, 97150, 97161, 97162, 97163, 97164, 97165, 97166, 97167, 97168, 97530 | <p>Procedure codes 97110, 97112, 97116, 97150, 97161, 97162, 97163, 97164, 97165, 97166, 97167, 97168, and 97530 reimbursable with a diagnosis of Z91.81.</p> |
| <p>Folic Acid for the Prevention of Neural Tube Defects: Preventive Medication</p> <p><u>USPSTF “A” Recommendation January 2017</u></p> <p>The USPSTF recommends that all women who are planning or capable of pregnancy take a daily supplement containing 0.4 to 0.8 mg (400 to 800 µg) of folic acid.</p> | | <p>For details about pharmacy benefit coverage, contact the number on the patient’s BCBSIL member card. A patient’s pharmacy benefit may be managed by a company other than BCBSIL.</p> <p>Prescription required for</p> |

| | | |
|--|--|---|
| | | both OTC and prescription medications. |
| Gestational Diabetes: Screening <u>USPSTF “B” Recommendation August 2021</u> The USPSTF recommends screening for gestational diabetes in asymptomatic pregnant persons at 24 weeks of gestation or after. Refer also to HRSA’s ‘Gestational Diabetes’ <u>recommendation</u> | 36415, 82947, 82948, 82950, 82951, 82952, 83036 | Payable with a pregnancy diagnosis |
| Gonorrhea <u>USPSTF “B” Recommendation September 2021</u> The USPSTF recommends screening for gonorrhea in sexually active women age 24 years and younger and in women 25 years or older who are at increased risk for infection. | 87801, 87590, 87591, 87592, 87850 | Payable with a diagnosis code in Diagnosis List 1 |
| Healthy Diet and Physical Activity for Cardiovascular Disease Prevention in Adults with Cardiovascular Risk Factors: Behavioral Counseling <u>USPSTF “B” Recommendation November 2020</u> The USPSTF recommends offering or referring adults with cardiovascular disease risk factors to behavioral counseling interventions to promote a healthy diet and physical activity. | 99385, 99386, 99387, 99395, 99396, 99397, G0438, G0439, G0446, S9452, S9470, 97802, 97803, 97804, G0270, G0271, 99078, 99401, 99402, 99403, 99404, 99411, 99412, G0473 | |
| Healthy Weight and Weight Gain in Pregnancy: Behavioral Counseling Interventions | 99384, 99385, 99386, 99394, 99395, 99396, 99401, 99402, | |

| | | |
|---|--|--|
| <p><u>USPSTF “B” Recommendation May 2021</u></p> <p>The USPSTF recommends that clinicians offer pregnant persons effective behavioral counseling interventions aimed at promoting healthy weight gain and preventing excess gestational weight gain in pregnancy.</p> | <p>99403, 99404, 99411, 99412</p> | |
| <p>Hepatitis B in Pregnant Women Screening</p> <p><u>USPSTF “A” Recommendation July 2019</u></p> <p>The USPSTF recommends screening for hepatitis B virus infection in pregnant women at their first prenatal visit.</p> | <p>80055, 86704, 86705, 86706, 86707, 87340, 87341, 80074, 80076, G0499, 36415</p> | <p>Payable with a pregnancy diagnosis, or a diagnosis code in Diagnosis List 1</p> |
| <p>Hepatitis B Virus Infection Screening</p> <p><u>USPSTF “B” Recommendation December 2020</u></p> <p>The USPSTF recommends screening for hepatitis B virus infection in adolescents and adults at increased risk for infection.</p> | <p>80055, 80074, 80076, 86704, 86705, 86706, 86707, 87340, 87341</p> | <p>Payable with a diagnosis code in Diagnosis List 1</p> |
| <p>Hepatitis C Screening</p> <p><u>USPSTF “B” Recommendation March 2020</u></p> <p>The USPSTF recommends screening for hepatitis C virus infection in adults aged 18 to 79 years.</p> | <p>86803, 86804, 87520, 87521 G0472, G0567</p> | <p>Payable with a pregnancy diagnosis, or a diagnosis code in Diagnosis List 1</p> |

| | | |
|---|---|--|
| <p>High Blood Pressure Screening in Adults</p> <p><u>USPSTF “A” Recommendation April 2021</u></p> <p>The USPSTF recommends screening for high blood pressure in adults aged 18 years or older. The USPSTF recommends obtaining measurements outside of the clinical setting for diagnostic confirmation before starting treatment.</p> | <p>93784, 93786, 93788, 93790, 99385, 99386, 99387, 99395, 99396, 99397, 99473, 99474</p> | <p>Procedure codes 93784, 93786, 93788, 93790, 99473, and 99474 are reimbursable at the preventive level when billed with one of the following diagnosis codes: R03.0, R03.1, Z01.30, Z01.31</p> |
| <p>Human Immunodeficiency Virus Infection Prevention Drug Pre-exposure Prophylaxis</p> <p><u>USPSTF “A” Recommendation June 2019</u></p> <p>The USPSTF recommends that clinicians offer preexposure prophylaxis (PrEP) with effective antiretroviral therapy to persons who are at high risk of HIV acquisition. See the Clinical Considerations section for information about identification of persons at high risk and selection of effective antiretroviral therapy.</p> <p><u>USPSTF “A” Recommendation August 2023</u></p> <p>The USPSTF recommends that clinicians prescribe preexposure prophylaxis using effective antiretroviral therapy to persons who are at increased risk of HIV acquisition to decrease the risk of acquiring HIV. Injectables are now added.</p> | <p>HIV/Creatine Testing</p> <p>82565, 82570, 82575, 87534, 87535, 87536, 87537, 87538, 87539</p> <p>Injection, cabotegravir, 1mg,</p> <p>HIV PrEP:</p> <p>J0739, J0738, J0752</p> <p>*87389, 87390, 87391, 87806, G0432, G0433, G0435, 36415, 86689, 86701, 86702, 86703, G0475, 80055, 80081, 86706, 87340, 87341, 80074, 80076, G0499, 86803, 86804, G0472,</p> | <p>Consistent with FAQs About Affordable Care Act Implementation Part 47, baseline and monitoring services related to PrEP medication are reimbursable at the preventive level. See the CPTs in the column to the left. Note: This list is not exhaustive.</p> <p>For details about benefit coverage, contact the number on the patient’s BCBSIL member card.</p> <p>For details about pharmacy benefit coverage, contact the number on the patient’s BCBSIL member card. A patient’s pharmacy benefit may be managed by a company other than BCBSIL.</p> <p>Coverage includes generic Truvada (emtricitabine/tenofovir disoproxil</p> |

| | | |
|---|--|--|
| | <p>81025, G0011, G0013, G0012</p> <p>*CPTs are not all specifically PrEP related and could be covered under other USPSTF, HRSA, and Bright Futures recommendations</p> | <p>fumarate) 200-300 mg tablets, Apretude (cabotegravir) 600 mg/ 3 mL intramuscular extended-release suspension, Yeztugo, and Descovy (emtricitabine-tenofovir alafenamide fumarate) 200-25 mg tablets when used for prevention with a prescription. Refer to the member's drug list for coverage details.</p> <p>Diagnosis Codes HIV Related: Z11.4, Z71.7, B20, Z29.81</p> |
| <p>Human Immunodeficiency Virus (HIV) Infection Screening for Non-Pregnant Adolescents and Adults</p> <p><u>USPSTF "A" Recommendation June 2019</u></p> <p>The USPSTF recommends that clinicians screen for HIV infection in adolescents and adults aged 15 to 65 years. Younger adolescents and older adults who are at increased risk should also be screened.</p> <p><i>Refer also to HRSA's 'HIV Screening and Counseling' recommendation</i></p> <p><i>Refer also to Bright Future's 'STI/HIV Screening' recommendation</i></p> | <p>87389, 87390, 87391, 87806, G0432, G0433, G0435</p> | <p>Payable with a diagnosis code in Diagnosis List 1</p> |

| | | |
|--|---|--|
| <p>Human Immunodeficiency Virus Infection Screening for Pregnant Women</p> <p><u>USPSTF “A” Recommendation June 2019</u></p> <p>The USPSTF recommends that clinicians screen all pregnant persons, , including those who present in labor or at delivery whose HIV status is unknown.</p> <p><i>Refer also to HRSA’s ‘HIV Screening and Counseling’ recommendation</i></p> <p><i>Refer also to Bright Future’s ‘STI/HIV Screening’ recommendation</i></p> | <p>36415, 80081, 86689, 86701, 86702, 86703, 87389, 87390, 87391, 87806, G0432, G0433, G0435, G0475</p> | <p>Payable with a pregnancy diagnosis or a diagnosis code in Diagnosis List 1</p> |
| <p>Hypertension in Adults: Screening</p> <p><u>USPSTF “A” Recommendation April 2021</u></p> <p>The U.S. Preventive Task Force recommends screening for hypertension in adults 18 years or older with office blood pressure measurements. The USPSTF recommends obtaining blood pressure measurements outside of the clinical setting for diagnostic confirmation before starting treatment.</p> | <p>93784, 93786, 93788, 93790, 99385, 99386, 99387, 99395, 99396, 99397, 99473, 99474</p> | <p>Procedure codes 93784, 93786, 93788, 93790, 99473, 99474 are payable at no member cost share when billed with the DX codes R03.0, R03.1, Z01.30, Z01.31</p> |
| <p>Intimate Partner Violence, Elder Abuse, and Abuse of Vulnerable Adults Screening</p> <p><u>USPSTF “B” Recommendation October 2018</u></p> <p>The U.S. Preventive Services Task Force (USPSTF) recommends that</p> | <p>99202, 99203, 99204, 99205, 99211, 99212, 99213, 99214, 99215, 99384, 99385, 99386, 99387, 99394, 99395,</p> | <p>Payable with a diagnosis code in Diagnosis List 1</p> |

| | | |
|---|---|--|
| <p>clinicians screen for intimate partner violence in women of reproductive age and provide or refer women who screen positive to ongoing support services.</p> | <p>99396, 99397, 99401, 99402, 99403, 99404, 99411, 99412, 99417, S0610, S0612, S0613</p> | |
| <p>Latent Tuberculosis Infection Screening</p> <p><u>USPSTF "B" Recommendation September 2016</u></p> <p>The USPSTF recommends screening for latent tuberculosis infection (LTBI) in populations at increased risk.</p> | <p>86480, 86481, 86580</p> | <p>Payable with a diagnosis code in Diagnosis List 1</p> |
| <p>Lung Cancer Screening</p> <p><u>USPSTF "B" Recommendation March 2021</u></p> <p>The USPSTF recommends annual screening for lung cancer with low-dose computed tomography (LDCT) in adults aged 50 to 80 years who have a 20 pack-year smoking history and currently smoke or have quit within the past 15 years. Screening should be discontinued once a person has not smoked for 15 years or develops a health problem that substantially limits life expectancy or the ability or willingness to have curative lung surgery.</p> | <p>G0296, 71271</p> | <p>Subject to medical policy criteria and may require preauthorization</p> <p>Eff. 01/01/2021 procedure code 71271 is reimbursable at the preventive level if it meets medical policy criteria and is billed with one of the following diagnosis codes: F17.200, F17.201, F17.210, F17.211, F17.220, F17.221, F17.290, F17.291, Z12.2, Z87.891</p> |

| | | |
|--|---|--|
| <p>Weight Loss to Prevent Obesity-Related Morbidity and Mortality in Adults: Behavioral Interventions</p> <p><u>USPSTF “B” Recommendation September 2018</u></p> <p>The USPSTF recommends that clinicians offer or refer adults with a body mass index (BMI) of 30 or higher (calculated as weight in kilograms divided by height in meters squared) to intensive, multicomponent behavioral interventions.</p> | <p>97802, 97803, 97804, 99385, 99386, 99387, 99395, 99396, 99397, 99401, 99402, 99403, 99404, 99411, 99412, 99078, G0447, G0473</p> | |
| <p>Obesity in Children and Adolescents Screening</p> <p><u>USPSTF “B” Recommendation June 2017</u></p> <p>The USPSTF recommends that clinicians screen for obesity in children and adolescents 6 years and older and offer them or refer them to comprehensive, intensive behavioral interventions to promote improvement in weight status.</p> | <p>97802, 97803, 99383, 99384, 99385, 99393, 99401, 99402, 99403, 99404, 99411, 99412, G0446, G0447, G0473</p> | |
| <p>Ocular Prophylaxis for Gonococcal Ophthalmia Neonatorum Preventive Medication</p> <p><u>USPSTF “A” Recommendation January 2019</u></p> <p>The USPSTF recommends prophylactic ocular topical medication for all newborns to prevent gonococcal ophthalmia neonatorum.</p> | | <p>When billed under inpatient medical</p> |

| | | |
|--|---|--|
| <p>Osteoporosis Screening</p> <p><u>USPSTF “B” Recommendation</u> <u>June 2018</u></p> <p>The USPSTF recommends screening for osteoporosis with bone measurement testing to prevent osteoporotic fractures in women 65 years and older.</p> <p>The USPSTF recommends screening for osteoporosis with bone measurement testing to prevent osteoporotic fractures in postmenopausal women younger than 65 years who are at increased risk of osteoporosis, as determined by a formal clinical risk assessment tool.</p> | <p>76977, 77078, 77080, 77081, 78350, 78351, G0130</p> | <p>Payable with a diagnosis code in Diagnosis List 1</p> |
| <p>Perinatal Depression: Preventive Interventions</p> <p><u>USPSTF “B” Recommendation</u> <u>February 2019</u></p> <p>The USPSTF recommends that clinicians provide or refer pregnant and postpartum persons who are at increased risk of perinatal depression to counseling interventions.</p> | <p>99385,99386, 99387, 99395, 99396, 99397, 99401, 99402, 99403, 99404, 96160, 96161, G0444</p> | <p>Payable with a diagnosis code in Diagnosis List 1</p> |
| <p>Phenylketonuria in Newborns Screening</p> <p><u>USPSTF “A” Recommendation</u> <u>March 2008</u></p> <p>The USPSTF recommends screening for phenylketonuria in newborns.</p> | <p>84030, 99381, S3620</p> | <p>Procedure codes 84030 and S3620 reimbursable at the preventive level for children 0-90 days old</p> |

| | | |
|---|---|---|
| <p>Prediabetes and Type 2 Diabetes Screening</p> <p><u>USPSTF “B” Recommendation August 2021</u></p> <p>The USPSTF recommends screening for prediabetes and type 2 diabetes in adults aged 35 to 70 years who have overweight or obesity. Clinicians should offer or refer patients with prediabetes to effective preventive interventions.</p> | <p>82947, 82948, 82950, 82951, 83036, 82952, 97802, 97803, 97804, 99401, 99402, 99403, 99404, G0270, G0271, G0447, G0473, S9470</p> | <p>Payable with a diagnosis code in Diagnosis List 1</p> |
| <p>Preeclampsia Screening</p> <p><u>USPSTF “B” Recommendation April 2017</u></p> <p>The USPSTF recommends screening for preeclampsia in pregnant women with blood pressure measurements throughout pregnancy.</p> | | <p>Preeclampsia screening is done through routine blood pressure measurements</p> |
| <p>Rh(D) Incompatibility Screening</p> <p><u>USPSTF “A” Recommendation February 2004</u></p> <p>The USPSTF strongly recommends Rh(D) blood typing and antibody testing for all pregnant women during their first visit for pregnancy-related care.</p> <p><u>USPSTF “B” Recommendation February 2004</u></p> <p>The USPSTF recommends repeated Rh(D) antibody testing for all unsensitized Rh(D)negative women at 24 to 28 weeks’ gestation, unless the biological father is known to be Rh(D)-negative.</p> | <p>80055, 86850, 86870, 86900, 86901, 36415</p> | <p>Payable with a pregnancy diagnosis</p> |

| | | |
|--|---|--|
| <p>Sexually Transmitted Infections Behavioral Counseling</p> <p><u>USPSTF “B” Recommendation August 2020</u></p> <p>The USPSTF recommends behavioral counseling for all sexually active adolescents and for adults who are at increased risk for sexually transmitted infections (STIs).</p> <p>Refer also to HRSA’s ‘Sexually Transmitted Infections Counseling’ recommendation.</p> | <p>99384, 99385, 99386, 99387, 99394, 99395, 99396, 99397, 99401, 99402, 99403, 99404, 99411, 99412, G0445</p> | |
| <p>Sickle Cell Disease (Hemoglobinopathies) in Newborns Screening</p> <p><u>USPSTF “A” Recommendation September 2007</u></p> <p>The USPSTF recommends screening for sickle cell disease in newborns.</p> | <p>83020, 83021, 83030, 83033, 83051, 85004, 85013, 85014, 85018, 85025, 85027, 99381, G0306, G0307, S3620, S3850</p> | |
| <p>Skin Cancer Counseling</p> <p><u>USPSTF “B” Recommendation March 2018</u></p> <p>The USPSTF recommends counseling young adults, adolescents, children, and parents of young children about minimizing exposure to ultraviolet (UV) radiation for persons aged 6 months to 24 years with fair skin types to reduce their risk of skin cancer.</p> | <p>There are no procedure codes specific to skin cancer counseling.</p> | |

| | | |
|---|--|---|
| <p>Statin Use for the Primary Prevention of Cardiovascular Disease in Adults Preventive Medication</p> <p><u>USPSTF “B” Recommendation August 2022</u></p> <p>The USPSTF recommends that clinicians prescribe a statin for the primary prevention of CVD for adults aged 40 to 75 years who have 1 or more CVD risk factors (i.e. dyslipidemia, diabetes, hypertension, or smoking) and an estimated 10-year risk of a cardiovascular event of 10% or greater.</p> | <p>80061, 82465, 83700, 83718, 83719, 83721, 84478</p> | <p>For details about pharmacy benefit coverage, contact the number on the patient’s BCBSIL member card. A patient’s pharmacy benefit may be managed by a company other than BCBSIL.</p> <p>Coverage includes atorvastatin 10 mg, 20 mg, 40 mg, and 80 mg, lovastatin 20 mg and 40 mg tablets, pravastatin 10 mg, 20 mg, 40 mg, and 80 mg tablets for members ages 40 – 75 years of age with a prescription.</p> |
| <p>Syphilis Infection in Nonpregnant Adults and Adolescents Screening</p> <p><u>USPSTF “A” Recommendation June 2016</u></p> <p>The USPSTF recommends screening for syphilis infection in persons who are at increased risk for infection.</p> | <p>86592, 86780, 0065U</p> | <p>Payable with a diagnosis code in Diagnosis List 1</p> |
| <p>Syphilis Infection in Pregnant Women Screening</p> <p><u>USPSTF “A” Recommendation May 2025</u></p> <p>The USPSTF recommends early, universal screening for syphilis infection during pregnancy; if an individual is not screened early in pregnancy, the USPSTF recommends screening at the first available opportunity.</p> | <p>80055, 80081, 86592, 86593, 86780, 0065U, 36415, 0210U, 87285</p> | <p>Payable with a pregnancy diagnosis or a diagnosis code in Diagnosis List 1</p> |

| | | |
|--|--|---|
| <p>Tobacco Smoking Cessation in Adults, Including Pregnant Women: Behavioral and Pharmacotherapy Interventions</p> <p><u>USPSTF “A” Recommendation January 2021</u></p> <p>The USPSTF recommends that clinicians ask all adults about tobacco use, advise them to stop using tobacco, and provide behavioral interventions and U.S. Food and Drug Administration–approved pharmacotherapy for cessation to adults who use tobacco.</p> <p><u>USPSTF “A” Recommendation January 2021</u></p> <p>The USPSTF recommends that clinicians ask all pregnant women about tobacco use, advise them to stop using tobacco, and provide behavioral interventions for cessation to pregnant women who use tobacco.</p> | <p>99401, 99402, 99403, 99404, 99406, 99407, S9453</p> | <p>For details about pharmacy benefit coverage, contact the number on the patient’s BCBSIL member card. A patient’s pharmacy benefit may be managed by a company other than BCBSIL.</p> <p>Two 90-day treatment regimens per benefit period. The 90-day treatments are at the discretion of the provider working with the member.</p> <p>Prescription required for both OTC and prescription medications.</p> <p>Coverage includes:</p> <ul style="list-style-type: none"> • Generic bupropion hcl (smoking deterrent) ER 12hr 150 mg tablets • Generic nicotine polacrilex 2 mg and 4 mg gum • Generic nicotine polacrilex 2 mg and 4 mg lozenges • Generic nicotine 24hr 7 mg, 14 mg, and 21 mg transdermal patches • Generic varenicline tartrate 0.5 mg and 1 mg tablets • Brand Nicotine Transdermal Systems • Brand Nicotrol Inhaler • Brand Nicotrol Nasal Spray |
|--|--|---|

| | | |
|--|--|--|
| Tobacco Use in Children and Adolescents Primary Care Interventions <u>USPSTF “B” Recommendation</u> <u>April 2020</u> The USPSTF recommends that primary care clinicians provide interventions, including education or brief counseling, to prevent initiation of tobacco use among school-aged children and adolescents. | 99401, 99402, 99403, 99404, 99406, 99407, S9453 | Refer to Preventive Services Recommendation for Tobacco Smoking Cessation in Adults, Including Pregnant Women: Behavioral and Pharmacotherapy Interventions |
| Screening for Unhealthy Drug Use <u>USPSTF “B” Recommendation</u> <u>June 2020</u> The USPSTF recommends screening by asking questions about unhealthy drug use in adults age 18 years or older. Screening should be implemented when services for accurate diagnosis, effective treatment, and appropriate care can be offered or referred. | 99385, 99386, 99387, 99395, 99396, 99397, 99408, 99409, G0396, G0397 | Payable with a diagnosis code in Diagnosis List 1 |
| Vision Screening in Children <u>USPSTF “B” Recommendation</u> <u>September 2017</u> The USPSTF recommends vision screening at least once in all children aged 3 to 5 years to detect amblyopia or its risk factors. | 99172, 99173, 0333T | |
| General Lab Panel These lab codes could be multiple Preventive Services recommendations. | 80050, 80053 | Payable with a diagnosis code in Diagnosis List 1 |
| | | |

| | | |
|---|--|--|
| | | |
| HRSA Recommendations: | | |
| Service: | Procedure Code(s): | Additional Reimbursement Criteria: |
| Anxiety Screening <u>HRSA Recommendation December 2019</u> The Women’s Preventive Services Initiative recommends screening for anxiety in adolescent and adult women, including those who are pregnant or postpartum. | 96127, 99384, 99385, 99386, 99387, 99394, 99395, 99396, 99397, G0444 | Procedure code 96127 is only reimbursable at the preventive level when billed with a diagnosis of Z00.129, Z13.31, Z13.32, Z13.39, Z13.41, or Z13.42 |
| Breast Cancer Screening for Women at Average Risk <u>HRSA Recommendation December 2026</u> The Women’s Preventive Services Initiative recommends that average-risk women initiate mammography screening no earlier than age 40 and no later than age 50. Screening mammography should occur at least biennially and as frequently as annually. Women may require additional imaging to complete the screening process or to address findings on the initial screening mammography. If additional imaging (e.g., magnetic resonance imaging (MRI), ultrasound, mammography) and pathology evaluation are indicated, these services also are recommended to complete the screening process for malignancies. Screening | 77061, 77062, 77063, 77067, 76376, 76377, 76641, 76642, 77046, 77048, 77049, 77065, 77066, C8903, C8905, C8906, C8908, C8937, G0279, 0633T, 0634T, 0635T, 0637T, 0638T, 19030, 77053, 77054 88108, 88112, 88172, 88173, 88184, 88185, 88262, 88271, 88274, 88291, 88300, 88304, 88305, 88307, 88309, 88312, 88313, 88325, 88331, 88332, 88341, 88342, 88344, 88360, | Payable if billed with diagnosis: Z00.00, Z00.01, Z00.8, Z01.411, Z12.31, and Z12.39 |

| | | |
|---|---|--|
| <p>should continue through at least age 74 and age alone should not be the basis to discontinue screening. These screening recommendations are for women at average risk of breast cancer. Women at increased risk should also undergo periodic mammography screening, however, recommendations for additional services are beyond the scope of this recommendation</p> <p>Refer also to USPSTF's 'Breast Cancer Screening' recommendation.</p> | <p>83361, 88364, 88365, 88367, 88374, & 88377</p> <p>19081, 19082, 19083, 19084, 19085, 19086, 19100, 19101, 19281, 19282, 19283, 19284, 19285, 19286, 19287, 19288, 10004, 10005, 10006, 10007, 10008, 10009, 10010, 10011 10012, 10021 C7501, & C7502</p> <p>A9500, A9502, A9503, A9520, A9537, A9541, A9552, A9561, A9573, A9575, A9576, A9577, A9577, A9578, A9579, A9581, A49585, A9595, Q9950, Q9953, Q9954, Q9957, Q9958, Q9962, Q9963, Q9966, Q9967, Q9968, Q9969, Q9067, Q9953 & Q9954 96374, 96375, 01922, 99152, 99153, 99156, 99157, 76942, 77002, 77012, 88177, 80503,</p> | |
|---|---|--|

| | | |
|--|--|--|
| | 80504, 80505, 80506 Patient Navigation Services: G0023, G0024, G0140, G0146 | |
| Breastfeeding Services and Supplies <u>HRSA Recommendation December 2021</u> Women's Preventive Services Initiative recommends comprehensive lactation support services (including consultation; counseling; education by clinicians and peer support services; and breastfeeding equipment and supplies) during the antenatal, perinatal, and postpartum periods to optimize the successful initiation and maintenance of breastfeeding. Breastfeeding equipment and supplies include, but are not limited to, double electric breast pumps (including pump parts and maintenance) and breast milk storage supplies. Access to double electric pumps should be a priority to optimize breastfeeding and should not be predicated on prior failure of a manual pump. Breastfeeding equipment may also include equipment and supplies as clinically indicated to support dyads with breastfeeding | E0602, E0603, E0604, A4281, A4282, A4283, A4284, A4285, A4286, A4287, G0513, G0514, S9443, 99401, 99402, 99403, 99404, 99411, 99412, 99347, 99348, 99349, 99350, 98960, 98961, 98962 , A4288 | Electric breast pumps limited to one per benefit period. Hospital Grade breast pumps are limited to rental only. G0513 & G0514 are payable with a diagnosis code in Diagnosis List 1 Additional reimbursement information available within the "Breastfeeding Equipment and Supplies" Coverage Non-physician provider types such as Certified Lactation Counselors and International Board-Certified Lactation Consultants will only be eligible for reimbursement for the following codes: S9443, 98960, 98961, 98962. |

| | | |
|--|--|--|
| <p>difficulties and those who need additional services.</p> <p><i>Refer also to USPSTF's 'Breastfeeding Primary Care Interventions' recommendation.</i></p> | | |
| <p>Cervical Cancer Screening</p> <p><u>HRSA Recommendation</u> <u>December 2019</u></p> <p>The Women's Preventive Services Initiative recommends cervical cancer screening for average-risk women aged 21 to 65 years. For women aged 21 to 29 years, the Women's Preventive Services Initiative recommends cervical cancer screening using cervical cytology (Pap test) every 3 years. Cotesting with cytology and human papillomavirus testing is not recommended for women younger than 30 years. Women aged 30 to 65 years should be screened with cytology and human papillomavirus testing every 5 years or cytology alone every 3 years. Women who are at average risk should not be screened more than once every 3 years.</p> <p><i>Refer also to USPSTF 'Cervical Cancer Screening' recommendation.</i></p> | <p>0096U, 87623, 87624, 87625, 88141, 88142, 88143, 88147, 88148, 88150, 88152, 88153, 88155, 88164, 88165, 88166, 88167, 88174, 88175, 99385, 99386, 99387, 99395, 99396, 99397, G0101, G0123, G0124, G0141, G0143, G0144, G0145, G0147, G0148, G0476, P3000, P3001, Q0091, S0610, S0612, 87626</p> | <p>Payable with a diagnosis code in Diagnosis List 1</p> |

| | | |
|--|---|---|
| <p>Contraceptive Methods and Counseling</p> <p><u>HRSA Recommendation</u> <u>December 2021</u></p> <p>Women's Preventive Services Initiative recommends that adolescent and adult women have access to the full range of contraceptives and contraceptive care to prevent unintended pregnancies and improve birth outcomes. Contraceptive care includes screening, education, counseling, and provision of contraceptives (including in the immediate postpartum period). Contraceptive care also includes follow-up care (e.g., management, evaluation and changes, including the removal, continuation, and discontinuation of contraceptives).</p> <p>Women's Preventive Services Initiative recommends that the full range of U.S. Food and Drug Administration - approved, granted, or -cleared contraceptives, effective family planning practices, and sterilization procedures be available as part of contraceptive care.</p> <p>The full range of contraceptives includes those currently listed in the FDA's Birth Control Guide: (1) sterilization surgery for women, (2) implantable rods, (3) copper intrauterine devices, (4) intrauterine devices with</p> | <p>57170, 58300, 58301, 58600, 58605, 58611, 58615, 58661, 58565, 58670, 58671, 58340, 58700, 74740, 88302, 88305, 96372, 11976, 11981, 11982, 11983, A4261, A4264, A4266, A4268, A4269, A9293, J1050, J7296, J7297, J7298, J7300, J7301, J7303, J7304, J7306, J7307, A4267, S4981, S4989</p> | <p>Contraception methods that require a prescription may be covered under the patient's medical or pharmacy benefit. For details about pharmacy benefit coverage for contraception, contact the number on the patient's BCBSIL member card. A patient's pharmacy benefit may be managed by a company other than BCBSIL.</p> <p>Visits pertaining to contraceptive counseling, initiation of contraceptive use, and follow-up care may also apply to procedure codes under HRSA's 'Well-Woman' recommendation</p> <p>Procedure code 58340 reimbursable at the preventive level only when accompanied with modifier 33 or one of the following diagnosis codes: Z30.2, Z30.40, Z30.42, Z30.49, Z98.51,</p> <p>Procedure codes 11981, 11982, and 11983 (are covered only when FDA approved contraceptive implant insertion or removal are performed) are reimbursable at the preventive level when</p> |
|--|---|---|

| | | |
|---|--|---|
| <p>progestin (all durations and doses), (5) injectable contraceptives, (6) oral contraceptives (combined pill), (7) oral contraceptives (progestin only),</p> | | |
| <p>(8) oral contraceptives (extended or continuous use), (9) the contraceptive patch, (10) vaginal contraceptive rings, (11) diaphragms, (12) contraceptive sponges, (13) cervical caps, (14) condoms, (15) spermicides, (16) emergency contraception (levonorgestrel), and (17) emergency contraception (ulipristal acetate), and any additional contraceptives approved, granted, or cleared by the FDA. Additionally, instruction in fertility awareness-based methods, including the lactation amenorrhea method, although less effective, should be provided</p> | | <p>billed with one of the following diagnosis codes: Z30.013, Z30.017, Z30.018, Z30.019, Z30.09, Z30.40, Z30.42, Z30.46, Z30.49, Z30.8, Z30.9 Procedure codes 58661, 58700 reimbursable at the preventive level with a diagnosis of Z30.2</p> <p>For details about pharmacy benefit coverage, contact the number on the patient's BCBSIL member card. A patient's pharmacy benefit may be managed</p> |

| | | |
|--|--|---|
| <p>for women desiring an alternative method. condoms, (15) spermicides, (16) emergency contraception (levonorgestrel), and (17) emergency contraception (ulipristal acetate), and any additional contraceptives approved, granted, or cleared by the FDA. Additionally, instruction in fertility awareness-based methods, including the lactation amenorrhea method, although less effective, should be provided for women desiring an alternative method.</p> | | <p>by a company other than BCBSIL.</p> <p>Prescription required for both OTC and prescription medications. For the list of contraceptive methods that may be covered, visit your health plan website.</p> <p>Procedure code 96372 payable with a diagnosis code in Diagnosis list 1</p> |
| <p>Diabetes Screening after Pregnancy</p> <p><u>HRSA Recommendation December 2019</u></p> <p>The Women's Preventive Services Initiative recommends women with a history of gestational diabetes mellitus who are not currently pregnant and who have not been previously diagnosed with type 2 diabetes mellitus should be screened for diabetes mellitus. Initial testing should ideally occur within the first year postpartum and can be conducted as early as 4–6 weeks postpartum. Women with a negative initial postpartum screening test result should be rescreened at least every 3 years for a minimum of 10 years after pregnancy. For women with a positive postpartum screening test result, testing to confirm the diagnosis of diabetes is indicated</p> | <p>82947, 82948, 82950, 82951, 83036</p> | <p>Payable with a diagnosis code in Diagnosis List 1</p> |

| | | |
|--|--|---|
| <p>regardless of the initial test (e.g., oral glucose tolerance test, fasting plasma glucose, or hemoglobin A1c). Repeat testing is indicated in women who were screened with hemoglobin A1c in the first 6 months postpartum regardless of the result.</p> | | |
| <p>Gestational Diabetes</p> <p><u>HRSA Recommendation</u> <u>December 2019</u></p> <p>The Women’s Preventive Services Initiative recommends screening pregnant women for gestational diabetes mellitus after 24 weeks of gestation (preferably between 24 and 28 weeks of gestation) in order to prevent adverse birth outcomes. Screening with a 50 g oral glucose challenge test (followed by a 3hour 100 g oral glucose tolerance test if results on the initial oral glucose challenge test are abnormal) is preferred because of its high sensitivity and specificity. The Women’s Preventive Services Initiative suggests that women with risk factors for diabetes mellitus be screened for preexisting diabetes before 24 weeks of gestation—ideally at the first prenatal visit,</p> | <p>82947, 82948, 82950, 82951, 83036</p> | <p>Payable with a pregnancy diagnosis</p> |

| | | |
|---|--|---|
| <p>based on current clinical best practices.</p> <p><i>Refer also to USPSTF's 'Gestational Diabetes Mellitus Screening' recommendation.</i></p> | | |
| <p>Human Immune-Deficiency Virus Counseling & Screening</p> <p><u>HRSA Recommendation December 2021</u></p> <p>Women's Preventive Services Initiative recommends all adolescent and adult women, ages 15 and older, receive a screening test for HIV at least once during their lifetime. Earlier or additional screening should be based on risk, and rescreening annually or more often may be appropriate beginning at age 13 for adolescent and adult women with an increased risk of HIV infection.</p> <p>Women's Preventive Services Initiative recommends risk assessment and prevention education for HIV infection beginning at age 13 and continuing as determined by risk.</p> | <p>36415, 86689, 86701, 86702, 86703, 87389, 87390, 87391, 87806, G0432, G0433, G0435, G0475</p> | <p>Payable when billed with a diagnosis code in on Diagnosis List 1</p> |

| | | |
|---|---|--|
| <p>A screening test for HIV is recommended for all pregnant women upon initiation of prenatal care with rescreening during pregnancy based on risk factors. Rapid HIV testing is recommended for pregnant women who present in active labor with an undocumented HIV status. Screening during pregnancy enables prevention of vertical transmission.</p> <p><i>Refer also to USPSTF's 'Human Immunodeficiency Virus (HIV) Infection Screening for Pregnant and Non-Pregnant Adolescents and Adults' recommendation.</i></p> <p><i>Refer also to Bright Future's 'STI/HIV Screening' recommendations.</i></p> | | |
| <p>Interpersonal and Domestic Violence Screening</p> <p><u>HRSA Recommendation December 2019</u></p> <p>The Women's Preventive Services Initiative recommends screening adolescents and women for interpersonal and domestic violence at least annually, and, when needed, providing or referring for initial intervention services. Interpersonal and domestic violence includes physical violence, sexual violence, stalking and psychological aggression (including coercion), reproductive coercion, neglect, and the threat of violence, abuse, or both. Intervention services include, but are not limited to, counseling, education, harm</p> | <p>99401, 99402, 99403, 99404, 99411, 99412, 99384, 99385, 99386, 99387, 99394, 99395, 99396, 99397, 99202, 99203, 99204, 99205, 99211, 99212, 99213, 99214, 99215, 99417</p> | <p>Payable when billed with a diagnosis code on Diagnosis List 1</p> |

| | | |
|---|--|--|
| reduction strategies, and referral to appropriate supportive services. | | |
| Obesity Prevention in Midlife Women <u>HRSA Recommendation December 2021</u> Women's Preventive Services Initiative recommends counseling midlife women aged 40 to 60 years with normal or overweight body mass index (BMI) (18.5-29.9 kg/m ²) to maintain weight or limit weight gain to prevent obesity. Counseling may include individualized discussion of healthy eating and physical activity. | 97802, 97803, 97804, 99078, 99386, 99396, 99401, 99402, 99403, 99404, 99411, 99412, G0447, G0473 | Payable when billed with a diagnosis code in on Diagnosis List 1 |

| | | |
|---|--|--|
| <p>Sexually Transmitted Infections Counseling</p> <p><u>HRSA Recommendation</u> <u>December 2021</u></p> <p>Women’s Preventive Services Initiative recommends directed behavioral counseling by a health care clinician or other appropriately trained individual for sexually active adolescent and adult women at an increased risk for STIs.</p> <p>Women’s Preventive Services Initiative recommends that clinicians review a woman’s sexual history and risk factors to help identify those at an increased risk of STIs. Risk factors include, but are not limited to, age younger than 25, a recent history of an STI, a new sex partner, multiple partners, a partner with concurrent partners, a partner with an STI, and a lack of or inconsistent condom use. For adolescents and women not identified as high risk, counseling to reduce the risk of STIs should be considered, as determined by clinical judgment.</p> <p><i>Refer also to USPSTF’s ‘Sexually Transmitted Infections Behavioral Counseling’ recommendation.</i></p> | <p>99401, 99402, 99403, 99404, 99411, 99412, 99384, 99385, 99386, 99387, 99394, 99395, 99396, 99397, G0445</p> | |
|---|--|--|

| | | |
|---|--|--|
| <p>Urinary Incontinence Screening</p> <p><u>HRSA Recommendation</u> <u>December 2019</u></p> <p>The Women’s Preventive Services Initiative recommends screening women for urinary incontinence annually. Screening should ideally assess whether women experience urinary incontinence and whether it impacts their activities and quality of life. The Women’s Preventive Services Initiative recommends referring women for further evaluation and treatment if indicated. The Women's Preventive Services Initiative recommends screening women for urinary incontinence as a preventive service. Factors associated with an increased risk for urinary incontinence include increasing parity, advancing age, and obesity; however, these factors should not be used to limit screening.</p> <p>Several screening tools demonstrate fair to high accuracy in identifying urinary incontinence in women. Although minimum screening intervals are unknown, given the prevalence of urinary incontinence, the fact that many women do not volunteer symptoms, and the multiple, frequently changing risk factors associated with incontinence, it is reasonable to conduct annually.</p> | <p>There are no procedure codes specific to this service. This service would be part of the preventive office visit.</p> | <p>Payable with a diagnosis code in Diagnosis List 1</p> |
|---|--|--|

| | | |
|--|---|--|
| <p>Well-Woman Visits</p> <p><u>HRSA Recommendation December 2021</u></p> <p>Women's Preventive Services Initiative recommends that women receive at least one preventive care visit per year beginning in adolescence and continuing across the lifespan to ensure the provision of all recommended preventive services, including preconception and many services necessary for prenatal and interconception care, are obtained. The primary purpose of these visits should be the delivery and coordination of recommended preventive services as determined by age and risk factors. These services may be completed at a single or as part of a series of visits that take place over time to obtain all necessary services depending on a woman's age, health status, reproductive health needs, pregnancy status, and risk factors. Well-women visits also include pre-pregnancy, prenatal, postpartum and interpregnancy visits.</p> | <p>99384, 99385, 99386, 99387, 99394, 99395, 99396, 99397, G0101, G0438, G0439, 99078, 99401, 99402, 99403, 99404, 99411, 99412, 99408, 99409, G0396, G0442, G0443, G0444</p> | <p>Labs administered as part of a normal pregnancy reimbursable at the preventive level when billed with a pregnancy diagnosis</p> |
| | | |
| ACIP Recommendations: | | |
| Service: | Procedure Code(s): | Additional Reimbursement Criteria: |
| COVID-19 Vaccine | 91318, 91319, 91320, 91321, 91322, 91304 | |

| | | |
|---|---|---|
| DTaP Vaccine | 90696, 90698, 90700, 90702, 90723 | |
| Hepatitis A Vaccine | 90632, 90633, 90634, 90636 | |
| Hepatitis B Vaccine | 90739, 90740, 90743, 90744, 90746, 90747, 90748, 90759 | Hepatitis B Vaccination is payable at the preventive level for newborns under 90 days of age when obtained in the inpatient setting from an in-network provider |
| Haemophilus Influenzae Type B (Hib) Vaccine | 90647, 90648 | |
| Human Papillomavirus Vaccine (HPV) | 90651 | Payable with a diagnosis code in Diagnosis List 1 |
| Influenza Vaccine | 90653, 90655, 90656, 90657, 90658, 90660, 90661, 90662, 90672, 90673, 90674, 90682, 90685, 90686, 90687, 90688, 90689, 90694, 90756 Q2034, Q2035, Q2036, Q2037, Q2038, Q2039, 90635 | |
| Measles, Rubella, Congenital Rubella Syndrome, and Mumps (MMR) | 90707 | |
| Measles, Mumps, Rubella, and Varicella (MMRV) | 90710 | |
| Meningococcal Vaccine | 90644, 90733, 90734, 90619, 90620, 90621, 90623 | |
| Monkeypox Vaccine | 90611 | |

| | | |
|--|--|---|
| Pneumococcal Vaccine | 90670, 90677, 90732, 90671, 90684 | |
| Polio Vaccine | 90713 | |
| Respiratory Syncytial Virus Immunization | 90380, 90381, 90382 90679, 90678, 90683, 91323 | |
| Rotavirus Vaccine | 90680, 90681 | |
| Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine (Tdap/Td) | 90714, 90715 | |
| Varicella Vaccine | 90716 | |
| Zoster (Shingles) Vaccine | 90750 | |
| Immunization Administration | 90460, 90461, 90471, 90472, 90473, 90474, 90749, 90480, 96380, 96381, 90481 | |
| | | |
| Bright Futures Recommendations: | | |
| Service: | Procedure Code(s): | Additional Reimbursement Criteria: |
| Alcohol Use and Drug Use Assessment <u>Bright Futures</u> Recommends alcohol and drug use assessments for adolescents between the ages of 11 to 21 years. | 99408, 99409 | Payable with a diagnosis code in Diagnosis List 1 |

| | | |
|--|--------------|--|
| Anemia Screening in Children <u>Bright Futures</u> Recommends anemia screening for children under the age of 21 years of age. | 85014, 85018 | Payable with a diagnosis code in Diagnosis List 1 For details about pharmacy benefit coverage, contact the number on the patient's BCBSIL member card. A patient's pharmacy benefit may be managed by a company other than BCBSIL. Prescription required for both OTC and prescription medications. Coverage provided for members up to 1 year of age. |
| Cervical Dysplasia Screening <u>Bright Futures</u> Recommends cervical dysplasia screening for adolescents age 21 years of age | Q0091 | Payable with a diagnosis code in Diagnosis List 1 |
| Critical Congenital Heart Defect Screening <u>Bright Futures</u> Recommends screening for critical congenital heart disease using pulse oximetry for newborns after 24 hours of age, before discharge from the hospital | 94760 | |
| Depression Screening <u>Bright Futures</u> Recommends depression screening for adolescents between the ages of 11 to 21 years | 96127 | Payable with a diagnosis code in Diagnosis List 1 |

| | | |
|---|--|---|
| Refer also to USPSTF's 'Depression in Children and Adolescents Screening' recommendation | | |
| Developmental Screening / Autism Screening <u>Bright Futures</u> Recommends developmental/autism screening for infants and young children between the ages of 9 months and 30 months | 96110 | Payable with a diagnosis code in Diagnosis List 1 |
| Dyslipidemia Screening <u>Bright Futures</u> Recommends dyslipidemia screening for children and adolescents between the ages of 24 months and 21 years of age | 80061, 82465, 83718, 84478 | Payable with a diagnosis code in Diagnosis List 1 |
| Hearing Screening <u>Bright Futures</u> Recommends hearing screenings for children and adolescents from birth through 21 years of age | 92558, 92567, 92551, 92650, 92651, 92652, 92653, V5008 | Procedure codes 92558, 92567, 92551, V5008 are payable at the preventive level only when billed with diagnosis codes Z01.10, Z01.118, and Z01.110 for ages 22 and under. Eff. 01/01/2021 CPT codes 92650, 92651, 92652, 92653 may be payable at the preventive level only when billed with diagnosis codes Z01.10, Z01.118, and Z01.11 through ages 22 and under if meeting Medical Policy criteria. |

| | | |
|--|---|---|
| Hematocrit or Hemoglobin <u>Bright Futures</u> Recommends hematocrit or hemoglobin screening for children and adolescents between the ages of four months and 21 years of age | 36415, 36416, 85014, 85018 | Payable with a diagnosis code in Diagnosis List 1 |
| HIV Screening | 87389, 87390, 87391, 87806, G0432, G0433, G0435 | Payable with a diagnosis code in Diagnosis List 1 |
| Lead Screening <u>Bright Futures</u> Recommends screening children between the ages of six months and six years for lead | 36415, 36416, 83655 | Payable with a diagnosis code in Diagnosis List 1 |
| Maternal Depression Screening | 99384, 99385, 99386, 99387, 99394, 99395, 99396, 99397, G0444 | |
| Newborn Bilirubin | 82247, 82248, 88720 | Payable with a diagnosis code in Diagnosis List 1 |
| Newborn Blood Screening | S3620 | Payable with a diagnosis code in Diagnosis List 1 |
| Oral Health <u>Bright Futures</u> Recommends oral health risk assessments beginning at six months of age | 99211, 99212, 99188, 99381, 99382, 99383, 99384 | Payable with a diagnosis code in Diagnosis List 1 |
| Prenatal Visit | 99401, 99402, 99403, 99404 | Payable with a diagnosis code in Diagnosis List 1 |
| Preventive Medicine Services: New Patients | 99381, 99382, 99383, 99384, 99385 | Payable with a diagnosis code in Diagnosis List 1 |
| Preventive Medicine Services: Established Patients | 99391, 99392, 99393, 99394, 99395 | Payable with a diagnosis code in Diagnosis List 1 |

| | | |
|--|--|---|
| STI/HIV Screening <u>Bright Futures</u> Recommends screening for all sexually active patients <i>Refer also to USPSTF's 'Human Immunodeficiency Virus (HIV) Infection Screening for Pregnant and Non-Pregnant Adolescents and Adults' recommendations</i> <i>Refer also to HRSA's 'Sexually Transmitted Infections Counseling' recommendation</i> | 86631, 86632, 86701, 86703, 87081, 87110, 87210, 87270, 87320, 87490, 87491, 87590, 87591, 87800, 87801, 87810, 87850, 36415 | Payable with a diagnosis code in Diagnosis List 1 |
| Tuberculosis Testing <u>Bright Futures</u> Recommends tuberculosis testing if the risk assessment is positive | 86580, 99211 | Payable with a diagnosis code in Diagnosis List 1 |
| Vision Screening <u>Bright Futures</u> Recommends vision screening for newborns through age 21 years | 99173 | Payable with a diagnosis code in Diagnosis List 1 |

Many of the services listed above may be performed for indications other than preventive care. In these situations, services may be covered by another provision of the individual's benefit plan and subject to applicable cost sharing.

Diagnosis List 1

| | | | | | | |
|---------|---------|---------|---------|---------|---------|---------|
| Z00.00 | Z00.01 | Z00.110 | Z00.111 | Z00.121 | Z00.129 | Z00.8 |
| Z01.411 | Z01.419 | Z02.83 | Z11.1 | Z11.3 | Z11.4 | Z11.51 |
| Z11.7 | Z12.11 | Z12.12 | Z12.2 | Z12.31 | Z12.39 | Z12.4 |
| Z12.5 | Z13.0 | Z13.1 | Z13.220 | Z13.31 | Z13.32 | Z13.40 |
| Z13.41 | Z13.42 | Z13.5 | Z13.6 | Z13.820 | Z20.2 | Z20.6 |
| Z23 | Z30.011 | Z30.012 | Z30.013 | Z30.014 | Z30.015 | Z30.016 |
| Z30.017 | Z30.018 | Z30.019 | Z30.02 | Z30.09 | Z30.40 | Z30.41 |
| Z30.42 | Z30.430 | Z30.431 | Z30.432 | Z30.433 | Z30.44 | Z30.45 |

| | | | | | | |
|--------|--------|--------|--------|--------|--------|--------|
| Z30.46 | Z30.49 | Z30.8 | Z30.9 | Z32.2 | Z71.41 | Z71.51 |
| Z71.6 | Z71.7 | Z71.82 | Z71.83 | Z86.32 | Z97.5 | R73.03 |
| Z29.81 | | | | | | |

Breastfeeding Equipment & Supplies

Non-grandfathered plans provide coverage of manual, electric, and hospital grade breast pumps along with breastfeeding supplies at the preventive level.

Manual breast pumps utilize procedure code E0602 and are available for purchase and covered at the preventive level when obtained In-Network, Out of Network, or from Retail providers. Sales tax is excluded from retail purchases.

Electric breast pumps utilize procedure code E0603 and must be rented or purchased from an InNetwork provider or a contracted durable medical equipment supplier. The models of breast pumps being provided at the preventive level are up to the individual provider's discretion. If a member chooses to obtain an upgraded model, they may be balance billed the difference between the allowance of the standard model and the cost of the upgraded model. Members are allowed one electric breast pump per benefit period.

*Note: Retail providers such as Target, Wal-Mart, or online vendor are not licensed medical providers and therefore are considered Out of Network. Out of network coverage will follow the out of network benefit level for preventive services. This may include cost sharing and sales tax is excluded. *

Hospital grade breast pumps utilize procedure code E0604 and are only covered when rented InNetwork or from an In-Network durable medical equipment supplier. Hospital grade breast pump coverage is up to the purchase price of \$1,000.00 or 12 months, whichever comes first. At the end of coverage, the unit must be returned to the durable medical equipment supplier. Members are allowed one breast pump per benefit period.

Breast pumps obtained from Out of Network providers are reimbursable at the Out of Network level.

The following breast pump supplies are reimbursable at the preventive level. Some limitations and restrictions may apply based on the group coverage for preventive services.

- A4281- Tubing for breast pump, replacement, spare membranes, replacements
- A4282- Adapter for breast pump, replacement

- A4283- Cap for breast pump bottle, replacement
- A4284- Breast shield and splash protector for use with breast pump, replacement
- A4285- Polycarbonate bottle for use with breast pump, replacement
- A4286- Locking ring for breast pump, replacement

Differentiating Preventive Care versus Diagnostic Care

The following types of services are considered Preventive:

- Screenings intended to prevent illness or identify issues before symptoms are evident
- Counseling intervention as defined by a specific preventive recommendation

Examples of preventive services:

- A 60-year-old woman obtains her biennial mammogram to screen for breast cancer
- A patient who has been identified as having cardiovascular disease risk factors is referred for nutritional counseling
- A 50-year-old patient obtains a colonoscopy to screen for colorectal cancer
- A 42-year-old patient goes to their doctor for their annual physical and receives a blood test to screen for abnormal blood glucose

The following types of services are considered Diagnostic:

- The diagnosis of existing symptoms or abnormalities
- Treatment for specific health conditions, ongoing care, or other tests to manage a health condition

Examples of diagnostic services:

- A 60-year-old woman obtains a mammogram after noticing a lump in her breast
- A patient diagnosed with diabetes is referred for nutritional counseling to manage their condition
- A patient goes to their doctor for their annual physical and receives a blood test to check iron and liver function, and a urinalysis is requested

Limitations and Exclusions

1. Services not reimbursable at the preventive level may be reimbursable under another portion of the medical plan.

2. Breastfeeding equipment and supplies not listed underneath the “Breastfeeding Equipment and Supplies” section. This includes, but is not limited to
 - a. Batteries
 - b. Breastfeeding ointments, creams
 - c. Breast milk storage supplies including bags, freezer packs, etc.
 - d. Breast pump cleaning supplies
 - e. Breast pump traveling cases
 - f. Infant scales
 - g. Nursing bras
 - h. Nursing covers, scarfs
3. Immunizations that are not published in the Center for Disease Control’s Morbidity and Mortality Weekly Report and/or are not on the list of “Vaccines Licensed for Use in the United States” by the United States Food and Drug Administration.
4. Prescription coverage may vary depending on the terms and conditions of the plans. A prescription may be required for coverage under the pharmacy benefit. The plan may also require that the generic drug be tried first before the brand version. Age limits, restrictions, and other requirements may apply. Members can verify their pharmacy benefits by calling the customer service number on the back of their ID card.
5. For OTC purchases, members will need to obtain a prescription from their provider and take it to the pharmacy to be filled.
6. Exceptions may apply, members can verify their pharmacy benefits by calling the customer service number on the back of their ID card.
7. If there is a medication not included, the member should consult their doctor for therapeutic alternatives first before submitting coverage exceptions to BCBSIL.

Each benefit plan, summary plan description or contract defines which services are covered, which services are excluded, and which services are subject to dollar caps or other limitations, conditions or exclusions. Members and their providers have the responsibility for consulting the member’s benefit plan, summary plan description or contract to determine if there are any exclusions or other benefit limitations applicable to this service or supply. If there is a discrepancy between a MEDICAL POLICY and a member’s benefit plan, summary plan description or contract, the benefit plan, summary plan description or contract will govern.

References

Advisory Committee on Immunization Practices. "[Vaccine-Specific ACIP Recommendations.](#)"

Retrieved March 1, 2022.

American Academy of Pediatrics- Bright Futures. "[Coding for Pediatric Preventive Care, 2022.](#)" Retrieved March 16, 2023.

American Academy of Pediatrics - Bright Futures. "[Recommendations for Preventive Pediatric Health Care.](#)" Retrieved March 1, 2023.

American Academy of Pediatrics- Bright Futures. "[Achieving Bright Futures.](#)" Retrieved March 16, 2023.

Centers for Disease Control and Prevention. "[Immunization Schedules.](#)" Retrieved March 1, 2022.

Health Resources and Services Administration. "[Women's Preventive Services Guidelines.](#)"

Retrieved December 15th, 2022.

United States Food and Drug Administration. "[Vaccines Licensed for Use in the United States.](#)" Retrieved March 1, 2022.

United States Preventive Services Task Force. "[Published Recommendations.](#)" Retrieved March 1, 2022.

Policy Update History

| Approval Date | Description |
|---------------|---|
| 06/23/2017 | New policy, replaces medical policy ADM1001.030 |
| 07/14/2017 | Removed codes 99174 and 99177. |
| 12/06/2017 | Coding and USPSTF updates |
| 04/30/2018 | Coding and USPSTF updates |
| 07/12/2018 | Coding and USPSTF updates |
| 12/27/2018 | Coding and USPSTF updates |
| 09/26/2019 | Coding and USPSTF updates |
| 10/14/2019 | HPV vaccine update |
| 12/30/2019 | Disclaimer, Coding and USPSTF updates |
| 04/20/2020 | Recommendation updates |
| 06/08/2020 | Disclaimer, Coding, Links, and recommendation updates |
| 09/09/2020 | Coding and recommendation updates |

| | |
|------------|---|
| 12/21/2020 | Coding and recommendation updates, drug information updates and disclaimers |
| 01/12/2021 | Coding updates |
| 09/22/2021 | Coding and recommendation updates, drug information updates |
| 12/16/2021 | Coding and USPSTF updates |
| 03/23/2022 | Coding and recommendation updates |
| 06/01/2022 | Coding and recommendation updates |
| 07/29/2022 | Diagnosis List 1 updates |
| 09/09/2022 | Coding and recommendation updates |
| 02/20/2023 | Coding updates |
| 03/16/2023 | Coding and recommendation updates, hyperlink updates |
| 5/24/2023 | Coding and recommendation updates |
| 06/01/2023 | Coding and recommendation updates |
| 09/25/2023 | Coding and recommendation updates |
| 09/27/2023 | Coding and recommendation updates |
| 12/18/2023 | Coding and recommendation updates |
| 3/22/2024 | Coding and recommendation updates |
| 06/01/2024 | Coding and recommendation updates |
| 08/29/2024 | Coding and recommendation updates |
| 02/01/2025 | Verbiage updates for Prep |
| 02/28/2025 | Coding and recommendation updates |
| 04/01/2025 | Coding and recommendation updates; CPT code 96040 removed and replaced with 96041; 0500T removed and replaced with 87626; added G0011, G0012, G0013, G0567; removed 90630 and 90654; added diagnosis code to Diagnosis List 1 Z29.8 |
| 07/01/2025 | Coding and recommendation updates; Adding Influenza vaccine code 90635. Update to USPSTF syphilis recommendation adding cpt codes 0210U&87285. Updating travel vaccine verbiage on pg1. |
| 08/29/2025 | Added codes 91323, 90382, A4288. Removed codes 90666, 90667, 90668. Yeztugo added to Human Immunodeficiency Virus Infection Prevention Drug Preexposure Prophylaxis section. |
| 12/01/2025 | Coding and recommendation updates; HRSA breast cancer screening mandate, new Prep injection codes. |

The Plan makes no endorsement, representations or warranties regarding any products or services offered by independent third-party vendors such as Target and Wal-Mart. These vendors are solely responsible for the products and services they offer. If you have any questions about the products or services offered by such vendors, you should contact the vendor(s) directly.